0001193125-13-254875.txt : 20130611 0001193125-13-254875.hdr.sgml : 20130611 20130611170854 ACCESSION NUMBER: 0001193125-13-254875 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130611 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20130611 DATE AS OF CHANGE: 20130611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GenMark Diagnostics, Inc. CENTRAL INDEX KEY: 0001487371 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 272053069 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34753 FILM NUMBER: 13906710 BUSINESS ADDRESS: STREET 1: 5964 LA PLACE COURT CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: (760) 448-4300 MAIL ADDRESS: STREET 1: 5964 LA PLACE COURT CITY: CARLSBAD STATE: CA ZIP: 92008 8-K 1 d552958d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2013

 

 

GENMARK DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-34753

 

Delaware   27-2053069

(State or other jurisdiction

of incorporation)

  

(I.R.S. Employer

Identification No.)

5964 La Place Court, Suite 100

Carlsbad, California

(Address of principal executive offices, including zip code)

760-448-4300

(Registrant’s telephone number, including area code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item. 7.01. Regulation FD Disclosure.

On June 11, 2013, Natural Molecular Testing Corporation (“NMTC”) and Luminex Corporation (“Luminex”) announced a partnership in connection with the launch by NMTC of its laboratory developed comprehensive Personalized Medicine Panel, comprised of 42 targets and built using Luminex’s technology.

This announcement has negatively affected the stock price of GenMark Diagnostics, Inc. (the “Company”). While the Company has not received notice from NMTC with respect to the Company’s agreement with NMTC and the agreement remains intact, the Company is currently evaluating the impact, if any, of this announcement on its relationship with NMTC and the associated business. The Company expects to file a current report on Form 8-K once this evaluation is complete.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    GENMARK DIAGNOSTICS, INC.
Date: June 11, 2013    

/s/ Eric Stier

    Eric Stier
    Senior Vice President and General Counsel